Product Code: RP-ID-10151776 |
Published Date: 21 Oct 2022 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10151776
Market Overview:
Global Rubella Diagnostic Testing Industry Market Research 2030
The rubella diagnostic testing market is expected to mark a CAGR of `5% over the period 2022-2030. The main growth drivers for the rubella diagnostic testing market are government actions to reduce rubella virus, the number of cases of rubella, and the introduction of advanced diagnostic technologies to boost overall rubella growth cases of rubella are increasing worldwide during the forecast period. Rubella is an acute contagious viral infection that causes mild fever and a skin rash in children and adults. Infection during pregnancy, especially early in pregnancy, can lead to miscarriage, stillbirth, fetal death, and birth defects. Rubella is a health risk, according to the U.S. Centers for Disease Control and Prevention (CDC). There are more than 100,000 cases of congenital rubella syndrome (CRS) each year worldwide. Women who get rubella early in pregnancy are up to 90% more likely to have a baby with congenital rubella syndrome. Scope of the report: For the purpose of the report, rubella testing includes the diagnosis of rubella virus. This test is prescribed for pregnant women and can also be done for babies with birth defects. Rubella can be diagnosed by a variety of diagnostic tests, such as latex agglutination, enzyme immunoassay, radioimmunoassay (RIA), and fluorescence immunoassay (FIA). Rubella Detection Market is Segmented Geographically by Laboratory Technologies. Key Market Trends: The EIA Under Test Technology segment holds the largest share of the global market. Detection of anti-rubella immunoglobulin (IgM) in serum is a standard test for the rapid diagnosis of rubella. The IgM test is the most common test method using a commercially available enzyme immunoassay (EIA) kit. Blood tests detect antibodies produced by the immune system to kill the rubella virus, and these antibodies remain in the bloodstream for years. Due to the high prevalence of rubella, this region is expected to hold the largest market share. Asia Pacific is the fastest growing market in the world: Asia Pacific region experienced the fastest growth rate for rubella diagnostic testing market and there was no similar trend and no change during the forecast period in this regard. Asia Pacific holds the largest market share due to growing untapped opportunities, a lack of awareness in some countries and government initiatives to contain the spread of the disease. According to the 2017 Global Vaccine Action Plan (GVAP) assessment report, 42 countries have not yet distributed the vaccine, and two regions in Africa and the Eastern Mediterranean have not set vaccination targets. Rubella removal or management. The rubella infection rate is expected to be high in this region, which could lead to further market growth. Competitive Approach: Few major players dominate the market under consideration, and most market players focus on developing new technologies to maximize market share. The presence of major market players such as Abbott Laboratories, Bio-Rad Laboratories Inc., Biomerieux SA, Siemens AG, Thermo Fisher Scientific, Inc. increases the competitiveness of the overall market. Major Players Abbott Bio Rad Laboratories Inc. bioM�rieux SA Siemens Healthcare GmbH Thermo Fisher Scientific Inc.
Related Reports
Proof of Quality & Reliability
